# Thymosin Alpha-1 Reconstitution and Dosing: Immune-Peptide Literature
> Note: PeptIQ is not a medical provider. This article is educational only. It is not a protocol.
Thymosin alpha-1 (Tα1) is a 28-amino-acid thymic peptide studied as an immune modulator. Romani and colleagues published a comprehensive literature review (PMC7747025, PMID 33172279). Tuthill, Rios, and McBeath discussed infectious-disease perspectives (PubMed 28493560). Garaci and colleagues reviewed adjuvant use in melanoma and other cancers (PubMed 25332085). ClinicalTrials.gov indexes thymosin alpha-1 studies (search).
In some markets a branded product (often discussed as Zadaxin / thymalfasin) carried infectious-disease and vaccine-adjuvant labeling. That product context is not the same as a research-use lyophilized listing.
Evidence tier
| Layer | What it supports | What it does not |
|---|
| Reviews and infectious-disease papers | Immune-modulator framing and study regimens | A universal consumer schedule |
| Branded thymalfasin history | Product-specific milligrams and routes where labeled | Identity of an unlabeled vial |
| Community logs | What people record in wellness settings | Medical advice |
Lyophilized-vial math
Educational write-ups use:
Concentration (mg/mL) = labeled mg ÷ diluent mL
Volume (mL) = desired mg ÷ concentration
Illustrative example only
A vial labeled 1.6 mg with 1 mL bacteriostatic water is 1.6 mg/mL, so a 1.6 mg discussion figure is 1.0 mL. A 3.2 mg vial with 2 mL is also 1.6 mg/mL. Those numbers show why 1.6 mg appears so often in both papers and forums. They are not a mixing instruction.
Bacteriostatic water is the diluent named most often for multi-draw research vials. Branded kits, when they exist, specify their own diluent. Follow that IFU instead of a generic chart. Refrigeration after reconstitution is the usual storage claim for research listings.
Research-reference ranges
Many infectious-disease and adjuvant papers discuss 1.6 mg subcutaneously on a twice-weekly cadence for defined courses. That figure is a study and product-tradition anchor. It is not automatically correct for an unlabeled powder, a different indication, or an open-ended wellness log.
| Source | Figure | Reading |
|---|
| Romani 2020 review and related papers | Study and product regimens, often 1.6 mg class amounts | Context-specific |
| Infectious-disease / adjuvant trials | Course length tied to the indication | Not a lifestyle peptide calendar |
| Community tables | 1.6 mg, 2x/week, variable duration | Uncontrolled copy of the study slogan |
PeptIQ users who log thymosin alpha-1 are fewer than those logging BPC-157 or MOTS-c. When they do, twice-weekly milligram-scale entries are the common pattern. That is observational. It is not a finding.
Route language
Published regimens typically describe subcutaneous administration. Some hospital protocols in the literature used other parenteral routes. Route lists are not an injection tutorial. Vaccine-adjuvant and oncology settings in papers are clinician-directed contexts.
Bottom line
Thymosin alpha-1 has a denser clinical literature than most peptides sold as research vials. The 1.6 mg twice-weekly figure is a study and product-tradition number. Reconstitution math is generic. Educational use only.
